Trixatumumab
From Wikipedia, the free encyclopedia
|
Trixatumumab
|
|
|
|
|
| Source | Human |
| Target | ? |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Trixatumumab is a human monoclonal antibody and which it is used to treat cancer.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Adalimumab, Adecatumumab, Anetumumab, Atorolimumab, Belimumab, Bertilimumab, Betumumab, Cetforlimumab, Cetinlimumab, Cetlalimumab, Cetolimumab, Cynosumab, Denosumab, Duntumumab, Durimulumab, Durmulumab, Efungumab, Exbivirumab, Futumumab, Genosumab, Golimumab, Intumumab, Ipilimumab, Iratumumab, Lerdelimumab, Lexatumumab, Libivirumab, Mapatumumab, Metelimumab, Nebacumab, Ofatumumab, Panitumumab, Pritumumab, Raxibacumab, Regavirumab, Resatumumab, Restumumab, Rosutumumab, Sevirumab, Stamulumab, Synosumab, Ticilimumab, Tritumumab, Trixatumumab, Tuvirumab, Vexatumumab, Votumumab, Zalutumumab, Zanolimumab, Ziralimumab
